Cerebral Atherosclerosis Research With Positron Emission Tomography

• Conditions: Cerebral Infarction

• Registration Number: NCT07041372
• Lead Sponsor: Seoul National University Hospital

Brief Summary

The goal of this clinical trial is to learn if the application of fluorodeoxyglucose positron emission tomography can predict prognosis of stroke patients. The main questions it aims to answer are:

* Does FDG PET can predict future vascular events such as stroke recurrence, myocardial infarction or vascular death among stroke survivors?

* Does FDG PET can predict other important events such as fracture, dementia, bleeding, cancer and overall death among stroke survivors? Researchers will compare the FDG uptake in major organs - such as the amygdala, vertebrae, spleen, liver, internal carotid artery, visceral fat, and psoas muscle - between patients with and without the event of interest to determine whether FDG PET can predict the overall prognosis of stroke patients.

Participants will:

* Undergo whole-body FDG PET once their neurological status has stabilized after stroke.

* Complete questionnaires assessing stress and anxiety (PHQ-9 and PSS-10) on the same day.

* Maintain regular clinic visits for up to 24 months following the index stroke

Detailed Description

Not available

Study Timeline

• Study Start: 2021-06-22
• Status Verified: 2025-06
• Study First Submitted: 2025-06-19
• Study First Submitted QC: 2025-06-19
• Last Update Submitted: 2025-06-19
• Study First Posted: 2025-06-27
• Last Update Posted: 2025-06-27
• Primary Completion: 2029-02-28
• Study Completion: 2029-08-31

Recruitment & Eligibility

• Status: ENROLLING_BY_INVITATION
• Sex: All
• Target Recruitment: 310

Inclusion Criteria

• acute ischemic stroke patients who admitted within seven days after symptom onset

Exclusion Criteria

• Patients with unstable vital signs or neurological symptoms
• Patients with estimated glomerular filtration rate less than 30ml/min
• Patients with uncontrolled diabetes requiring persistent insulin injection
• During pregnancy or while breastfeeding
• Patients with impaired consent capacity
• Patients with diagnosed/treatment for dementia
• Patients undergoing treatment for malignant tumors or serious autoimmune diseases

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Vascular events	up to 24 months after index stroke	Stroke, myocardial infarction, vascular death

Secondary Outcome Measures

Name	Time	Method
overall vascular events	up to 24 months after index stroke	primary vascular events plus transient ischemic attack, venous thromboembolism, peripheral artery disease requiring intervention or hospitalization

Trial Locations

Locations (1)

Seoul National University Hospital; 🇰🇷 Seoul, Jong-ro Gu, Korea, Republic of